Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
المصدر: Nasdaq GlobeNewswire / 08 أبريل 2024 05:30:43 America/Chicago